INSMED Inc 8-K, filed May 18, 2021
INSMED Inc (INSM)
8-K
2021-05-18
For: 2021-05-12
View Original
Added on
April 09, 2026
About this 8-K
INSMED Inc filed this 8-K on May 18, 2021, reporting on events of May 12, 2021.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 12, 2021
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
(Zip Code)
|
|
|
(Address of principal executive offices)
|
Registrant’s telephone number, including area code: (908 ) 977-9900
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On May 12, 2021, at the annual meeting of shareholders of Insmed Incorporated (the “Company” and the “Annual Meeting”), the Company’s
shareholders approved Amendment No. 2 to the Insmed Incorporated 2019 Incentive Plan (the “2019 Incentive Plan”), which was previously adopted by the Company’s Board of Directors.
A summary of the material terms and conditions of the 2019 Incentive Plan is included in the Company’s definitive proxy statement filed with
the Securities and Exchange Commission on April 1, 2021 (the “Proxy Statement”) under “Proposal No. 4: Amendment No. 2 to the Insmed Incorporated 2019 Incentive Plan,” which summary is incorporated herein by reference. This summary is qualified in
its entirety by, and should be read in conjunction with, (i) the 2019 Incentive Plan, which was attached as Exhibit 10.5 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, (ii) Amendment No. 1 to the 2019
Incentive Plan, which was attached as Exhibit 10.5.1 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, (iii) Omnibus Amendment to Insmed Incorporated Incentive Plans, which was attached as Exhibit 10.6 to the
Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and (iv) Amendment No. 2 to the 2019 Incentive Plan, which was included as Appendix A to the Proxy Statement.
ITEM 5.07 – Submission of Matters to a Vote of Security Holders.
A total of 103,270,236 shares of the Company’s common stock were entitled to vote as of March 19, 2021, the record date for the Annual
Meeting. There were 93,953,612 shares present in person or by proxy at the Annual Meeting, at which shareholders voted on four proposals. Set forth below are the matters acted upon by the shareholders, and the final
voting results of each such matter.
Proposal 1. Election of Four Class III Directors.
By the following votes, shareholders elected David R. Brennan, Leo Lee, Carol A. Schafer, and Melvin Sharoky, M.D. to serve as Class III
directors until the Company’s 2024 Annual Meeting of Shareholders:
|
For
|
Withheld
|
Broker Non-Votes
|
|||
|
David R. Brennan
|
87,486,614
|
911,550
|
5,555,448
|
||
|
Leo Lee
|
87,465,126
|
933,038
|
5,555,448
|
||
|
Carol A. Schafer
|
86,523,272
|
1,874,892
|
5,555,448
|
||
|
Melvin Sharoky, M.D.
|
86,116,532
|
2,281,632
|
5,555,448
|
Proposal 2. Advisory Vote on the 2020 Compensation of Named Executive Officers.
By the following vote, shareholders approved, on an advisory, non-binding basis, the compensation of our named executive officers, as
disclosed in the Proxy Statement:
|
For
|
Against
|
Abstentions
|
Broker Non-Votes
|
|||
|
85,416,649
|
2,703,419
|
278,096
|
5,555,448
|
Proposal 3. Ratification of the Appointment of an Independent Registered Public Accounting Firm.
By the following vote, shareholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public
accounting firm for the year ending December 31, 2021:
|
For
|
Against
|
Abstentions
|
||
|
92,239,439
|
1,440,254
|
273,919
|
Proposal 4. Approval of Amendment No. 2 to the Insmed Incorporated 2019 Incentive Plan.
By the following vote, shareholders approved Amendment No. 2 to the 2019 Incentive Plan to increase the number of shares authorized for
issuance thereunder:
|
For
|
Against
|
Abstentions
|
Broker Non-Votes
|
|||
|
82,926,525
|
5,193,742
|
277,897
|
5,555,448
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
Dated: May 18, 2021
|
INSMED INCORPORATED
|
|
|
By:
|
/s/ Christine Pellizzari
|
|
|
Name:
|
Christine Pellizzari
|
|
|
Title:
|
Chief Legal Officer
|
|